CSL Seqirus has welcomed the announcement that neffy adrenaline nasal spray will be listed on the Pharmaceutical Benefits Scheme on 1 July, making the product reimbursed for emergency treatment of anaphylaxis in adults and some children.
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News

